Lancet SCIE

國際簡稱：LANCET 參考譯名：柳葉刀

主要研究方向：醫(yī)學(xué)-醫(yī)學(xué)：內(nèi)科非預(yù)警期刊審稿周期：約3月

《柳葉刀》(Lancet)是一本由Elsevier Ltd出版的以醫(yī)學(xué)-醫(yī)學(xué)：內(nèi)科為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

1區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
218 年發(fā)文量
98.4 IF影響因子
未開放 是否OA
700 H-index
1823 創(chuàng)刊年份
Weekly 出版周期
English 出版語言

The Lancet is an international general medical journal that will consider any original contribution that advances or illuminates medical science or practice, or that educates or entertains the journal's readers. Whatever you have written, remember that it is the general reader whom you are trying to reach. One way to find out if you have succeeded is to show your draft to colleagues in other specialties. If they do not understand, neither, very probably, will The Lancet's staff or readers. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal.

[ 查看全部 ]

投稿咨詢加急咨詢

Lancet期刊信息

ISSN：0140-6736
出版語言：English
是否OA：未開放
E-ISSN：1474-547X
出版地區(qū)：ENGLAND
是否預(yù)警：否
出版商：Elsevier Ltd
出版周期：Weekly
創(chuàng)刊時間：1823
開源占比：0.2118
Gold OA文章占比：25.97%
OA被引用占比：0.1541...
出版國人文章占比：0.04
出版撤稿占比：
研究類文章占比：76.15%

Lancet CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

148.1

12.113

23.15

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：General Medicine	Q1	1 / 636	99%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Lancet中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué)：內(nèi)科	1區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué)：內(nèi)科	1區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué)：內(nèi)科	1區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué)：內(nèi)科	1區(qū)

Lancet JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, GENERAL & INTERNAL	SCIE	Q1	1 / 325	99.8%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, GENERAL & INTERNAL	SCIE	Q1	2 / 329	99.54%

Lancet歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Lancet中國學(xué)者發(fā)文選摘

1、Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Author: Hurvitz, Sara A.; Hegg, Roberto; Chung, Wei-Pang; Im, Seock-Ah; Jacot, William; Ganju, Vinod; Chiu, Joanne Wing Yan; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altintas, Sevilay; Henning, Jan-Willem; Curigliano, Giuseppe; Perez-Garcia, Jose Manuel; Kim, Sung-Bae; Petry, Vanessa; Huang, Chiun-Sheng; Li, Wei; Frenel, Jean-Sebastien; Antolin, Silvia; Yeo, Winnie; Bianchini, Giampaolo; Loi, Sherene; Tsurutani, Junji; Egorov, Anton; Liu, Yali; Cathcart, Jillian; Ashfaque, Shahid; Cortes, Javier

Journal: LANCET. 2023; Vol. 401, Issue 10371, pp. 105-117. DOI: 10.1016/S0140-6736(22)02420-5
2、Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferioritytrial
Author: Wang, Yongjun; Li, Shuya; Pan, Yuesong; Li, Hao; Parsons, Mark W.; Campbell, Bruce C., V; Schwamm, Lee H.; Fisher, Marc; Che, Fengyuan; Dai, Hongguo; Li, Deyang; Li, Runhui; Wang, Junhai; Wang, Yilong; Zhao, Xingquan; Li, Zixiao; Zheng, Huaguang; Xiong, Yunyun; Meng, Xia

Journal: LANCET. 2023; Vol. 401, Issue 10377, pp. 645-654. DOI: 10.1016/S0140-6736(22)02600-9
3、Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis
Author: Pan, Yang; Wang, Liang; Feng, Zhaomin; Xu, Hui; Li, Fu; Shen, Ying; Zhang, Daitao; Liu, William J.; Gao, George F.; Wang, Quanyi

Journal: LANCET. 2023; Vol. 401, Issue 10377, pp. 664-672. DOI: 10.1016/S0140-6736(23)00129-0
4、Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Author: Kimball, Alexa B.; Jemec, Gregor B. E.; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B.; Bechara, Falk G.; Paul, Carle; Bourboulis, Evangelos J. Giamarellos; Villani, Axel P.; Schwinn, Andreas; Rueff, Franziska; Ramaya, Larisha Pillay; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Martorell, Antonio; Mendes-Bastos, Pedro; Kokolakis, Georgios; Becherel, Pierre-Andre; Wozniak, Magdalena B.; Martinez, Angela Llobet; Wei, Xiaoling; Uhlmann, Lorenz; Passera, Anna; Keefe, Deborah; Martin, Ruvie; Field, Clarice; Chen, Li; Vandemeulebroecke, Marc; Ravichandran, Shoba; Muscianisi, Elisa

Journal: LANCET. 2023; Vol. 401, Issue 10378, pp. 747-761. DOI: 10.1016/S0140-6736(23)00022-3
5、Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Author: You, Rui; Liu, You -Ping; Xie, Yu -Long; Lin, Chao; Duan, Chong -Yang; Chen, Dong-Ping; Pan, Yi; Qi, Bin; Zou, Xiong; Guo, Ling; Cao, Jing-Yu; Zhang, Yi-Nuan; Wang, Zhi-Qiang; Liu, Yong -Long; Ouyang, Yan-Feng; Wen, Kai; Yang, Qi; Xie, Ruo-Qi; Li, Hui-Feng; Duan, Xiao-Tong; Ding, Xi; Peng, Lan; Chen, Si -Yuan; Liang, Jiong-Lin; Feng, Zheng-Kai; Xia, Tian-Liang; Xie, Rui-Ling; Jiang, Rou; Gu, Chen-Mei; Liu, Rong-Zeng; Sun, Rui; Yang, Xin; Liu, Li-Zhi; Ling, Li; Liu, Qing; Ng, Wai Tong; Hua, Yi-Jun; Huang, Pei-Yu; Chen, Ming-Yuan

Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 917-927. DOI: 10.1016/S0140-6736(23)00269-6
6、Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomisedtrial
Author: He, Jiang; Ouyang, Nanxiang; Guo, Xiaofan; Sun, Guozhe; Li, Zhao; Mu, Jianjun; Wang, Dao Wen; Qiao, Lixia; Xing, Liying; Ren, Guocheng; Zhao, Chunxia; Yang, Ruihai; Yuan, Zuyi; Wang, Chang; Shi, Chuning; Liu, Songyue; Miao, Wei; Li, Guangxiao; Chen, Chung-Shiuan; Sun, Yingxian; CRHCP Study Grp

Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 928-938. DOI: 10.1016/S0140-6736(22)02603-4
7、Malnutrition in older adults
Author: Dent, Elsa; Wright, Olivia R. L.; Woo, Jean; Hoogendijk, Emiel O.

Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 951-966. DOI: 10.1016/S0140-6736(22)02612-5
8、Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial
Author: Mingguang He, Yuzhen Jiang, Shengsong Huang, Dolly S Chang, Beatriz Munoz, Tin Aung, Paul J Foster, David S Friedman

Journal: LANCET, 2019, Vol., , DOI:10.1016/s0140-6736(18)32607-2